1-6 of 6
Jürgen Machann
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Empagliflozin Improves Insulin Sensitivity of the Hypothalamus in Humans With Prediabetes: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial

Stephanie Kullmann, Julia Hummel, Robert Wagner, Corinna Dannecker, Andreas Vosseler, Louise Fritsche, Ralf Veit, Konstantinos Kantartzis, Jürgen Machann, Andreas L. Birkenfeld, Norbert Stefan, Hans-Ulrich Häring, Andreas Peter, Hubert Preissl, Andreas Fritsche, Martin Heni
Journal: Diabetes Care
Diabetes Care 2022;45(2):398–406
https://doi.org/10.2337/dc21-1136
Published: 29 October 2021
View article titled, Empagliflozin Improves Insulin Sensitivity of the Hypothalamus in Humans With Prediabetes: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial
Open the PDF for Empagliflozin Improves Insulin Sensitivity of the Hypothalamus in Humans With Prediabetes: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial in another window
Journal Articles

Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial

Sabine Kahl, Sofiya Gancheva, Klaus Straßburger, Christian Herder, Jürgen Machann, Hisayuki Katsuyama, Stefan Kabisch, Elena Henkel, Stefan Kopf, Merit Lagerpusch, Konstantinos Kantartzis, Yuliya Kupriyanova, Daniel Markgraf, Theresa van Gemert, Birgit Knebel, Martin F. Wolkersdorfer, Oliver Kuss, Jong-Hee Hwang, Stefan R. Bornstein, Christian Kasperk, Norbert Stefan, Andreas Pfeiffer, Andreas L. Birkenfeld, Michael Roden
Journal: Diabetes Care
Diabetes Care 2020;43(2):298–305
https://doi.org/10.2337/dc19-0641
Published: 20 September 2019
View article titled, Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial
Open the PDF for Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial in another window
Includes: Supplementary data
Journal Articles

Leptin Replacement Reestablishes Brain Insulin Action in the Hypothalamus in Congenital Leptin Deficiency

Sabine Frank-Podlech, Julia von Schnurbein, Ralf Veit, Martin Heni, Jürgen Machann, Jaana M. Heinze, Stephanie Kullmann, Jaida Manzoor, Saqib Mahmood, Hans-Ulrich Häring, Hubert Preissl, Martin Wabitsch, Andreas Fritsche
Journal: Diabetes Care
Diabetes Care 2018;41(4):907–910
https://doi.org/10.2337/dc17-1867
Published: 24 January 2018
View article titled, Leptin Replacement Reestablishes Brain Insulin Action in the Hypothalamus in Congenital Leptin Deficiency
Open the PDF for Leptin Replacement Reestablishes Brain Insulin Action in the Hypothalamus in Congenital Leptin Deficiency in another window
Journal Articles

Selective Insulin Resistance in Homeostatic and Cognitive Control Brain Areas in Overweight and Obese Adults

Stephanie Kullmann, Martin Heni, Ralf Veit, Klaus Scheffler, Jürgen Machann, Hans-Ulrich Häring, Andreas Fritsche, Hubert Preissl
Journal: Diabetes Care
Diabetes Care 2015;38(6):1044–1050
https://doi.org/10.2337/dc14-2319
Published: 20 March 2015
View article titled, Selective Insulin Resistance in Homeostatic and Cognitive Control Brain Areas in Overweight and Obese Adults
Open the PDF for Selective Insulin Resistance in Homeostatic and Cognitive Control Brain Areas in Overweight and Obese Adults in another window
Includes: Supplementary data
Journal Articles

Circulating Lysophosphatidylcholines Are Markers of a Metabolically Benign Nonalcoholic Fatty Liver

Rainer Lehmann, PHD, Holger Franken, PHD, Sascha Dammeier, PHD, Lars Rosenbaum, PHD, Konstantinos Kantartzis, MD, Andreas Peter, MD, Andreas Zell, PHD, Patrick Adam, MD, Jia Li, PHD, Guowang Xu, PHD, Alfred Königsrainer, MD, Jürgen Machann, PHD, Fritz Schick, MD, Martin Hrabé de Angelis, PHD, Matthias Schwab, MD, Harald Staiger, PHD, Erwin Schleicher, PHD, Amalia Gastaldelli, PHD, Andreas Fritsche, MD, Hans-Ulrich Häring, MD, Norbert Stefan, MD
Journal: Diabetes Care
Diabetes Care 2013;36(8):2331–2338
https://doi.org/10.2337/dc12-1760
Published: 11 July 2013
View article titled, Circulating Lysophosphatidylcholines Are Markers of a Metabolically Benign Nonalcoholic Fatty Liver
Open the PDF for Circulating Lysophosphatidylcholines Are Markers of a Metabolically Benign Nonalcoholic Fatty Liver in another window
Includes: Supplementary data
Journal Articles

Circulating Palmitoleate Strongly and Independently Predicts Insulin Sensitivity in Humans

Norbert Stefan, MD, Konstantinos Kantartzis, MD, Nora Celebi, MD, Harald Staiger, PHD, Jürgen Machann, PHD, Fritz Schick, MD, PHD, Alexander Cegan, PHD, Michaela Elcnerova, PHD, Erwin Schleicher, PHD, Andreas Fritsche, MD, Hans-Ulrich Häring, MD
Journal: Diabetes Care
Diabetes Care 2010;33(2):405–407
https://doi.org/10.2337/dc09-0544
Published: 11 November 2009
View article titled, Circulating Palmitoleate Strongly and Independently Predicts Insulin Sensitivity in Humans
Open the PDF for Circulating Palmitoleate Strongly and Independently Predicts Insulin Sensitivity in Humans in another window
Includes: Supplementary data